Retatrutida

Retatrutid is a novel peptide-based drug that functions as a triple receptor agonist, simultaneously targeting GLP-1, GIP, and glucagon receptors. It facilitates weight loss through comprehensive regulation of appetite by enhancing satiety, suppressing hunger, and increasing energy expenditure. Additionally, Retatrutid demonstrates significant improvements in multiple cardiometabolic risk indicators including blood pressure, glycated hemoglobin (HbA1c), fasting blood glucose, insulin levels, total cholesterol, LDL cholesterol, and triglycerides. It also exerts positive effects on patients with non-alcoholic fatty liver disease (NAFLD), normalizing hepatic fat content in the majority of participants.

Compared to single or dual agonists, Retatrutid uniquely activates three receptors (GLP-1, GIP, and GCG) simultaneously, enabling multidimensional regulation of blood glucose and body weight. This multi-target mechanism theoretically allows for more comprehensive improvement of metabolic disorders, demonstrating distinct advantages in weight reduction, amelioration of hepatic steatosis, and normalization of blood glucose levels. The synergistic action of multiple receptors renders Retatrutid more effective than existing GLP-1 receptor agonists or dual agonists in metabolic regulation and weight management, offering a novel therapeutic option for individuals with obesity and type 2 diabetes.